COMPANY

Jubilant Therapeutics

HQ: Yardley, PA source · jubilanttx.com ↗

Keywords: hematology essential thrombocythemia small molecule Brain Metastases From Solid Tumors Leptomeningeal Disease High Grade Glioma Glioblastoma Myelodysplastic/Myeloproliferative Neoplasms Myeloproliferative Neoplasms JBI-802 JBI-778

Location: Yardley, PA · source · Oct 14, 2026

Profile checked Oct 10, 2026

3Trials (company is sponsor)

Timeline

Apr 1, 2028 Trial start 1: Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma source ↗
Oct 21, 2024 Trial start 1: Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) Wi source ↗
Apr 8, 2022 Trial start Phase 1/Phase 2: A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors source ↗

Upcoming milestones

Jun 15, 2028 (ESTIMATED) · 1 · Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With · NCT07612280
Mar 31, 2030 (ESTIMATED) · 1 · Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma · NCT07751744

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 3

Record	Title	Phase	Status	Start	Primary completion
NCT07751744	Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma	1	Not yet recruiting	Apr 1, 2028	Mar 31, 2030 (estimated)
NCT07612280	Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis	1	Recruiting	Oct 21, 2024	Jun 15, 2028 (estimated)
NCT05268666	A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors	Phase 1/Phase 2	Unknown status (ClinicalTrials.gov)	Apr 8, 2022	2024-12 (estimated)